Using an IO dataset of nivolumab-treated renal cancer patients, we found that:
- PD1 or PDL1 expression didn't predict survival
- PD1 activity (from RIDDEN) did associate with survival.
This shows that receptor activity could be a more effective biomarker than expression. 5/n